We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+13.64%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$894M
AUM Growth
-$17.6M
(-1.9%)
Cap. Flow
-$98M
Cap. Flow
% of AUM
-10.96%
Top 10 Holdings %
Top 10 Hldgs %
38.65%
Holding
76
New
8
Increased
23
Reduced
28
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$30.1M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$14M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$11.4M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$9.85M |
| 5 |
ARRY
Array Biopharma Inc
ARRY
|
+$8.51M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$23.5M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$17.6M |
| 3 |
TSRO
TESARO, Inc.
TSRO
|
+$12.9M |
| 4 |
Edwards Lifesciences
EW
|
+$12.5M |
| 5 |
Abbott
ABT
|
+$12.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.98% |
| 2 | Technology | 0.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Rocket Pharmaceuticals
RCKT
$345M
| $4.66M | 0.52% |
237,158
+21,000
| +10% | +$397K |
|
52
PTC Therapeutics
PTCT
$6.11B
| $4.58M | 0.51% |
135,884
-302,050
| -69% | -$9.42M |
|
53
MeiraGTx Holdings
MGTX
$1.1B
| $4.3M | 0.48% |
+375,000
| New | +$5.03M |
|
|
MASI
54
DELISTED
Masimo
MASI
| $4.12M | 0.46% |
42,201
-30,599
| -42% | -$2.91M |
|
55
Indaptus Therapeutics
INDP
$237M
| $3.92M | 0.44% |
397
+196
| +98% | +$2.17M |
|
|
VCRA
56
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $3.9M | 0.44% |
+130,650
| New | +$3.47M |
|
57
Savara
SVRA
$1.08B
| $3.75M | 0.42% |
331,500
+58,500
| +21% | +$587K |
|
58
Nektar Therapeutics
NKTR
$2.35B
| $3.6M | 0.4% |
4,908
-1,686
| -26% | -$1.94M |
|
59
Q32 Bio
QTTB
$450M
| $2.93M | 0.33% |
7,972
-4,528
| -36% | -$1.62M |
|
60
AnaptysBio
ANAB
$1.58B
| $2.42M | 0.27% |
+34,100
| New | +$2.86M |
|
|
CELG
61
DELISTED
Celgene Corp
CELG
| $1.84M | 0.21% |
23,212
-282,918
| -92% | -$23.5M |
|
|
FSTX
62
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $1.56M | 0.17% |
32,914
| – | – |
|
|
CMTA
63
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| $1.48M | 0.17% |
112,213
| – | – |
|
64
Zai Lab
ZLAB
$2.12B
| $1.13M | 0.13% |
48,668
-916
| -2% | -$19.8K |
|
|
SHPG
65
DELISTED
Shire pic
SHPG
| $760K | 0.09% |
+4,500
| New | +$726K |
|
66
Dr. Reddy's Laboratories
RDY
$9.73B
| $695K | 0.08% |
107,985
-19,495
| -15% | -$123K |
|
|
SRRA
67
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $597K | 0.07% |
5,042
| – | – |
|
|
68
Acadia Pharmaceuticals
ACAD
$4.39B
| – | – |
-783,424
| Closed | -$17.6M |
|
69
Accuray
ARAY
$30.1M
| – | – |
-384,547
| Closed | -$1.92M |
|
70
Glaukos
GKOS
$8.78B
| – | – |
-329,199
| Closed | -$10.1M |
|
71
Integra LifeSciences
IART
$1.58B
| – | – |
-123,198
| Closed | -$6.82M |
|
72
Neurocrine Biosciences
NBIX
$18.2B
| – | – |
-111,402
| Closed | -$9.24M |
|
73
Vertex Pharmaceuticals
VRTX
$123B
| – | – |
-41,915
| Closed | -$6.83M |
|
|
MNTA
74
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| – | – |
-264,699
| Closed | -$4.8M |
|
|
TSRO
75
DELISTED
TESARO, Inc.
TSRO
| – | – |
-225,260
| Closed | -$12.9M |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q2 2018 Portfolio in Review
As of Q2 2018, Sectoral Asset Management held 76 positions worth $894M, down 1.9% from $912M the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Sectoral Asset Management withdrew a net $98M in Q2 2018, closing 9 positions and reducing 28 holdings. Its most notable exit was Acadia Pharmaceuticals, an estimated $17.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier, followed by Technology.
Against the trend, Sectoral Asset Management opened a new position in Alnylam Pharmaceuticals worth $29.9M.
- Sectoral Asset Management's largest Q2 2018 buy was Alnylam Pharmaceuticals: 303,700 shares worth $29.9M.
- Sectoral Asset Management added most to Portola Pharmaceuticals, Inc. in Q2 2018, an estimated $11.4M increase.
- Sectoral Asset Management's biggest Q2 2018 reduction was Celgene Corp, cutting an estimated $23.5M.
- Sectoral Asset Management fully exited Acadia Pharmaceuticals in Q2 2018, selling an estimated $17.6M.
- Sectoral Asset Management's ten largest holdings make up 39% of its $894M portfolio in Q2 2018.
- Sectoral Asset Management opened 8 new positions and closed 9 in Q2 2018.
- Sectoral Asset Management's portfolio value fell 1.9% quarter-over-quarter to $894M.
Based on Sectoral Asset Management's 13F filing for Q2 2018, filed 13 Aug 2018.